Recombinant Virus Encoding One Or More Heterologous Proteins Or Fragments Thereof Patents (Class 424/199.1)
-
Patent number: 9616119Abstract: A mutant HSV-1 (referred to herein as KOS-NA) was generated. KOS-NA contains novel mutations in the UL39 gene, which encodes for a protein that is a large subunit of ribonucleotide reductase (i.e., ICP6). These UL39 mutations were found to alter two amino acids in ICP6 (R950H and L393P) and are responsible for attenuation of KOS-NA in vivo, and resulted in diminished ICP6 protein levels. These novel UL39 mutations regulate the expression and/or stability of ICP6 and severely impact HSV-1 pathogenesis. Mutant HSV viruses containing these mutations appear to protect against HSV infection and can serve as therapeutic vaccines to help combat preexisting HSV infection in infected individuals.Type: GrantFiled: March 24, 2015Date of Patent: April 11, 2017Assignee: University of KansasInventors: David J. Davido, Lynda Anne Morrison
-
Patent number: 9616118Abstract: The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease.Type: GrantFiled: May 2, 2014Date of Patent: April 11, 2017Assignee: MERIAL, INC.Inventors: Michel Bublot, Frederic Reynard, François-Xavier Le Gros
-
Patent number: 9593340Abstract: The present invention discloses methods and compositions for modulating the quality of an immune response to a target antigen in a mammal, which response results from the expression of a polynucleotide that encodes at least a portion of the target antigen, wherein the quality is modulated by replacing at least one codon of the polynucleotide with a synonymous codon that has a higher or lower preference of usage by the mammal to confer the immune response than the codon it replaces.Type: GrantFiled: October 2, 2008Date of Patent: March 14, 2017Assignee: Admedus Vaccines Pty Ltd.Inventors: Ian Hector Frazer, Julie Louise Dutton
-
Patent number: 9580693Abstract: The invention provides compositions and methods useful to prepare segmented, negative strand RNA viruses, e.g., orthomyxoviruses such as influenza A viruses, entirely from cloned cDNAs and in the absence of helper virus.Type: GrantFiled: October 2, 2015Date of Patent: February 28, 2017Assignee: Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Gabriele Neumann
-
Patent number: 9572876Abstract: The present invention includes methyltransferase (MTase)-defective recombinant viruses as live vaccine candidates for human metapneumovirus (hMPV), human respiratory syncytial virus (hRSV), and human parainfluenza virus type 3 (PIV3). Here the inventors provide the technical description for generating MTase-defective paramyxoviruses useful as immunogens, as well as related materials and methods.Type: GrantFiled: June 11, 2012Date of Patent: February 21, 2017Assignee: Ohio State Innovation FoundationInventors: Jianrong Li, Yu Zhang, Rongzhang Wang
-
Patent number: 9567606Abstract: The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. In a particular example, the invention provides vectors encoding a Rabies G immunogenic polypeptide and a canine OX40L genetic adjuvant, which vectors elicit strong immune responses in canine against rabies virus.Type: GrantFiled: February 14, 2013Date of Patent: February 14, 2017Assignee: MERIAL INC.Inventors: Teshome Mebatsion, Jules Maarten Minke, Frederic David
-
Patent number: 9566329Abstract: Disclosed herein are isolated rubella viral vector constructs that include a rubella non-structural protein open reading frame (ORF) without an in-frame deletion, a rubella structural protein ORF, and a heterologous antigenic insert. In one example, the heterologous antigenic insert is positioned within the rubella structural protein ORF. In some examples, the heterologous antigenic insert is positioned in the rubella structural protein ORF in between a gene encoding structural protein E2 and a gene encoding structural protein E1. Exemplary antigenic inserts include HIV, SIV, RSV or hepatitis B surface antigens. In some examples, the HIV antigenic insert is a Gag antigenic insert, a gp41 antigenic insert or a gp120 antigenic insert. Also disclosed are uses of the isolated rubella viral vector, such as to induce an immune response to a particular virus, such as HIV-1, testing sensitivity to neutralizing antibodies, or screening antiviral drugs (such as protease inhibitors).Type: GrantFiled: April 8, 2013Date of Patent: February 14, 2017Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Ira Berkower, Konstantin Virnik
-
Patent number: 9555096Abstract: The present invention provides recombinant herpesvirus of turkeys (HVT) vectors that contain and express antigens of avian pathogens, compositions comprising the recombinant HVT vectors, polyvalent vaccines comprising the recombinant HVT vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant HVT vectors.Type: GrantFiled: June 23, 2015Date of Patent: January 31, 2017Assignee: MERIAL, INC.Inventors: Michel Bublot, Teshome Mebatsion, Joyce Pritchard, Perry Linz
-
Patent number: 9555101Abstract: The present invention provides compositions or vaccines that contain a recombinant EHV-1 that elicit an immune response in animals against equine herpesvirus, including compositions comprising the recombinant EHV-1, methods of vaccination against equine herpesvirus, and kits for use with such methods and compositions.Type: GrantFiled: November 17, 2014Date of Patent: January 31, 2017Assignee: Merial, Inc.Inventors: Jean Christophe Audonnet, Jules Maarten Minke, Nikolaus Osterrieder, Guanggang Ma
-
Patent number: 9555090Abstract: Disclosed herein are nucleotide sequences which encode a plurality of structural proteins, except the capsid, of an equine encephalitis virus, wherein the nucleotide sequence is codon-optimized for mammalian expression. The nucleotide sequences are codon-optimized for expression in humans. As disclosed herein, the nucleotide sequences confer protection against Venezuelan equine encephalitis virus (VEEV), western equine encephalitis virus (WEEV), and/or eastern equine encephalitis virus (EEEV).Type: GrantFiled: May 25, 2012Date of Patent: January 31, 2017Assignee: The United States of America as repesented by the Secretary of Army, on behalf of the U.S. Army Medical Research Institute of Infections DiseasesInventors: Lesley Dupuy, Connie S. Schmaljohn
-
Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
Patent number: 9555089Abstract: The present disclosure relates to adenovirus protein modifications to augment immune response to a transgene of a recombinant adenovirus and to circumvent pre-existing anti-adenovirus immunity. Some embodiments are directed to a recombinant adenovirus derived from a recombinant adenovirus plasmid vector, wherein the recombinant adenovirus plasmid vector comprises a nucleotide sequence encoding a Plasmodium circumsporozoite protein, or antigenic portion thereof, operably linked to a heterologous promoter and a modified capsid or core protein, wherein an immunogenic epitope of Plasmodium circumsporozoite is inserted into or replaces at least part of a capsid or core protein. Other embodiments are directed to a pharmaceutical composition or a malaria vaccine composition comprising a recombinant adenovirus according to the above embodiments.Type: GrantFiled: February 17, 2012Date of Patent: January 31, 2017Assignee: THE ROCKEFELLER UNIVERSITYInventors: Takayuki Shiratsuchi, Moriya Tsuji -
Patent number: 9493528Abstract: Provided are small peptide fragments derived from microphthalmia-associated transcription factor (MITF) and a method for preventing or treating melanoma using the same as an active ingredient. Further provided is a method for skin-whitening and/or for inhibiting skin pigmentation, using the peptide fragments as an active ingredient.Type: GrantFiled: January 7, 2014Date of Patent: November 15, 2016Assignees: SUPADELIXIR INC., KNU-INDUSTRY COOPERATION FOUNDATIONInventors: Kyeong-Han Park, Jang-Hee Hahn, Dong-Young Lim
-
Patent number: 9492528Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA of type A/California/04/09 in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein of type A/California/04/09 and plants lipids. The invention is also directed to a nucleic acid encoding influenza HA of type A/California/04/09 as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.Type: GrantFiled: July 2, 2009Date of Patent: November 15, 2016Assignee: MEDICAGO INC.Inventors: Marc-Andre D'Aoust, Manon Couture, Frédéric Ors, Sonia Trepanier, Pierre-Olivier Lavoie, Michèle Dargis, Louis-Philippe Vezina, Nathalie Landry
-
Patent number: 9458470Abstract: A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines.Type: GrantFiled: January 23, 2013Date of Patent: October 4, 2016Assignee: MEDICAGO INC.Inventors: Marc-Andre D'Aoust, Manon Couture, Frederic Ors, Sonia Trepanier, Pierre-Olivier Lavoie, Michele Dargis, Louis-Philippe Vezina, Nathalie Landry
-
Patent number: 9458221Abstract: Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which encodes the E6 or E7 protein of HPV. The immunity generated is long term.Type: GrantFiled: August 23, 2013Date of Patent: October 4, 2016Assignee: VAXum, LLCInventors: Albert B. Deisseroth, Lixin Zhang
-
Patent number: 9446118Abstract: The present invention encompasses recombinant Newcastle Disease Virus-Herpesvirus vaccines or compositions. The invention encompasses recombinant NDV vectors encoding and expressing herpesvirus pathogen, antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals against disease.Type: GrantFiled: February 6, 2015Date of Patent: September 20, 2016Assignee: Merial, Inc.Inventors: Michel Bublot, Frederic Reynard, Herve Poulet, Frederic Raymond David
-
Patent number: 9441205Abstract: Reverse engineering has offered new ways of studying the pathology of RNA viral infections, new more efficient devices of synthesizing recombinant viruses and developing vaccines and also demonstrated the versatility and efficiency of RNA dependent RNA polymerase RDRP system as an expression system. However, the currently used methods require a repertoire of complex, difficult-to-use tools. Present invention describes, a simpler plasmid based mammalian expression system that uses the RDRP enzyme activity for expression of recombinant proteins or RNA from viral minigenomes and rescue of recombinant viruses from cDNAs encoding entire genome(s) of negative stranded RNA viruses. This system will be useful for expression of recombinant proteins, therapeutic RNA molecules including anti-sense and/or selecting interfering RNA and Ribozymes. This system can also be used for gene therapy and producing recombinant viruses for production of new vaccines.Type: GrantFiled: June 8, 2012Date of Patent: September 13, 2016Inventor: Vishwas Joshi
-
Patent number: 9422347Abstract: The present invention relates to the production of malaria transmission blocking vaccines in single-celled green algae, particularly algae of the genus Chlamydomonas, e.g., Chlamydomonas reinhardtii; the immunogenic Plasmodium polypeptides produced and compositions comprising them; and methods for preventing, ameliorating, reducing, delaying, treating and blocking the transmission of malaria by administration of immunogenic Plasmodium polypeptides produced in an algal host cell.Type: GrantFiled: May 1, 2012Date of Patent: August 23, 2016Assignee: The Regents of the University of CaliforniaInventors: Stephen P. Mayfield, James A. Gregory, Carla S. Jones, Michael J. Hannon
-
Patent number: 9409954Abstract: Recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.Type: GrantFiled: November 5, 2014Date of Patent: August 9, 2016Assignee: Intervet Inc.Inventors: Stephanie Cook, Mohamad Morsey, Gary Petersen, Paulus Jacobus Antonius Sondermeijer
-
Patent number: 9408804Abstract: The present invention pertains to a method for keeping an immunogenic composition available for administration to an animal, wherein said composition comprises an antigen and an emulsion which is a single emulsion at a first temperature below a body temperature of the animal and which emulsion reverses at a second temperature between the first temperature and the body temperature, said method comprising providing the composition, freezing the composition, and storing the frozen composition until it is needed for administration to the animal. The invention also pertains to a method for testing an immunogenic composition, and an immunogenic composition, optionally in combination with specific instructions for storing the composition.Type: GrantFiled: May 18, 2010Date of Patent: August 9, 2016Assignee: Intervet Inc.Inventors: Nicolaas Visser, Theodorus Jansen
-
Patent number: 9402895Abstract: An immunogenically-enhanced Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen 1 (“KSHV LANA1”) polypeptide and related methods of eliciting an immune response to KSHV LANA1 are provided. Also described herein is a novel polypeptide capable of inhibiting degradation of a protein or retarding synthesis of a protein when attached to or incorporated within that protein.Type: GrantFiled: December 22, 2011Date of Patent: August 2, 2016Assignee: University of Pittsburg—Of the Commonwealth System of Higher EducationInventors: Yuan Chang, Patrick S. Moore
-
Patent number: 9347065Abstract: The present invention relates to methods of developing gene inserts that are more compatible with the host vectors by modifying a protein sequence to lessen potential interference with vector propagation while ensuring that the protein is expressed and processed efficiently and maintains desired structural features, and designing a gene with a nucleotide sequence that resembles the base composition of the host vector genome.Type: GrantFiled: March 10, 2013Date of Patent: May 24, 2016Assignee: INTERNATIONAL AIDS VACCINE INITIATIVEInventors: Christopher L. Parks, Kevin J. Wright, Maoli Yuan, Christy K. Jurgens, Xinsheng Zhang, Arban Domi, Simon Hoffenberg, Maria J. Chiuchiolo, Svetlana Rabinovich, Aaron J. Wilson, Ivo C. Lorenz
-
Patent number: 9328146Abstract: The present invention relates to the design of gene transfer vectors and especially provides lentiviral gene transfer vectors suitable for either a unique administration or for iterative administration in a host, and to their medicinal application (such as vaccination against Immunodeficiency Virus, especially suitable in human hosts). Gene transfer vectors can be either integrative or non-integrative vectors. The invention encompasses prophylactic, therapeutic, symptomatic, and curative treatments of animals, including humans, as well as gene therapy and vaccination in vivo.Type: GrantFiled: March 5, 2014Date of Patent: May 3, 2016Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, THERAVECTYSInventors: Pierre Charneau, Anne-Sophie Beignon, Frederic Philippe Coutant, Karine Courbeyrette
-
Patent number: 9284532Abstract: The present invention relates to mammalian cells capable of propagating Arterivirus, to such cells infected with Arterivirus, to cell cultures comprising such cells and to methods for the propagation of an Arterivirus in such cells.Type: GrantFiled: December 17, 2013Date of Patent: March 15, 2016Assignee: Intervet Inc.Inventors: Lars Guelen, Carla Christina Schrier
-
Patent number: 9273120Abstract: Isolated peptides of the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01-107, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01-107 are disclosed. Also disclosed are isolated peptides of the Small Pox Virus Surface Antigen S Precursor Protein, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the Small Pox Virus Surface Antigen S Precursor Protein.Type: GrantFiled: September 13, 2013Date of Patent: March 1, 2016Inventors: Samuel Bogoch, Elenore S. Bogoch
-
Patent number: 9261512Abstract: The present invention concerns biomarkers and use thereof for determining whether a subject is or is not susceptible to developing a prophylactic or therapeutic immune response after such treatment.Type: GrantFiled: July 6, 2010Date of Patent: February 16, 2016Assignee: Transgene, S.A.Inventors: Bruce Acres, Benoit Grellier
-
Patent number: 9233153Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.Type: GrantFiled: October 5, 2012Date of Patent: January 12, 2016Assignee: GenVec, Inc.Inventors: Jason G. D. Gall, Duncan McVey, Douglas E. Brough
-
Patent number: 9217158Abstract: This invention provides replication-defective flavivirus vaccines and vaccine vectors, and corresponding compositions and methods.Type: GrantFiled: October 2, 2012Date of Patent: December 22, 2015Assignee: Sanofi Pasteur Biologics, LLCInventors: Konstantin V. Pugachev, Maryann Giel-Moloney, Harold Kleanthous, Mark Parrington, Linong Zhang
-
Patent number: 9192661Abstract: Particle compositions comprising adsorbed RNA replicons as well as methods of making and using the same are described.Type: GrantFiled: June 7, 2011Date of Patent: November 24, 2015Assignee: Novartis AGInventors: Siddhartha Jain, Derek O'Hagan, Manmohan Singh
-
Patent number: 9175040Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: July 25, 2008Date of Patent: November 3, 2015Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
-
Patent number: 9163237Abstract: The present invention relates to a replication deficient recombinant virus encoding at least one antigen and/or antigenic epitope, wherein expression of said antigen and/or antigenic epitope is regulated by a transcriptional control element comprising at least two elements driving early expression of said antigen and/or antigenic epitope and the use of said replication deficient recombinant virus as medicament or vaccine.Type: GrantFiled: December 4, 2013Date of Patent: October 20, 2015Assignee: BAVARIAN NORDIC A/SInventors: Jürgen Hausmann, Karen Baur, Kay Brinkmann
-
Patent number: 9157071Abstract: A modified Herpes Simplex Virus (HSV), which has a portion of gD (glycoprotein D) of the glycoproteic envelope deleted and a heterologous single chain antibody inserted in place of such deleted portion; the modified HSV is capable of infecting cells through receptor HER2/ErbB2 but not through receptors HVEM/HveA and nectin1/HveC; uses of the modified HSV and a process of the preparation thereof are also disclosed.Type: GrantFiled: November 24, 2010Date of Patent: October 13, 2015Assignee: ALMA MATER STUDIORUM-UNIVERSITA DI BOLOGNAInventors: Gabriella Campadelli, Laura Menotti
-
Patent number: 9139620Abstract: Described herein are isolated paramyxovirus, a morbillivirus (FmoPV), nucleic acid molecules, polypeptides and antibodies related to FmoPV and uses thereof. In certain embodiments, the FmoPV is a feline morbillivirus. Also described herein is a recombinant FmoPV comprising a modified FmoPV gene or gene segments and uses thereof. Also described is a recombinant FmoPV for the prevention and/or treatment of diseases related to FmoPV or a delivery vector. Also described herein is a diagnostic assay for FmoPV, natural or artificial variants, analogs, or derivatives thereof. Also described herein is a vaccine and a kit containing the vaccine for the prevention and treatment of FmoPV infection. Also provided is a diagnostic kit comprising nucleic acid molecules for the detection of FmoPV.Type: GrantFiled: January 22, 2013Date of Patent: September 22, 2015Assignees: THE GOVERNMENT OF THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, VERSITECH LIMITEDInventors: Kwok-Yung Yuen, Patrick Chiu-Yat Woo, Susanna Kar-Pui Lau
-
Patent number: 9101598Abstract: The present invention provides recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain and express antigens of avian pathogens, recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain a mutated gC gene, compositions comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors, polyvalent vaccines comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant Gallid herpesvirus 3 (MDV-2) vectors.Type: GrantFiled: November 29, 2012Date of Patent: August 11, 2015Assignee: MERIAL, INC.Inventors: Michel Bublot, Teshome Mebatsion, Joyce Pritchard, Perry Linz
-
Patent number: 9028837Abstract: The present invention provides methods and compositions for modulating an immune response in a subject, comprising administering to the subject an effective amount of an A35R protein or active fragment thereof of vaccinia virus or other poxvirus.Type: GrantFiled: December 20, 2012Date of Patent: May 12, 2015Assignee: East Carolina UniversityInventor: Rachel Roper
-
Patent number: 9023365Abstract: A recombinant transfer vector capable of expressing a foreign gene fused to a viral gene under the control of dual promoters and a recombinant baculovirus, and methods for production thereof, as well as pharmaceuticals comprising the recombinant baculovirus as an active ingredient.Type: GrantFiled: February 8, 2007Date of Patent: May 5, 2015Assignees: Educational Foundation Jichi Medical University, Otsuka Pharmaceutical Co., Ltd.Inventors: Shigeto Yoshida, Yoshio Ohba, Norimitsu Hariguchi, Masami Mizukoshi, Masanori Kawasaki, Makoto Matsumoto, Yoshihiro Goto
-
Patent number: 9023648Abstract: The invention is directed to a chimeric gammaretrovirus comprising an gammaretroviral virion which contains a lentiviral Vpx protein and methods of use thereof. In a particular aspect, the chimeric gammaretrovirus is a chimeric murine leukemia virus (MLV) comprising an MLV virion which contains a lentiviral Vpx protein. The invention is also directed to use of the chimeric gammaretrovirus to produce a MLV that can transduce a non-dividing cell (G1/S/G2), transduce a non-dividing cell; enhance the ability of a MLV to transduce a non-dividing cell; transduce a quiescent (G0) cell; and enhance the ability of a human immunodeficiency virus 1 (HIV-1) to transduce a quiescent (G0) cell.Type: GrantFiled: December 29, 2010Date of Patent: May 5, 2015Assignee: University of MassachusettsInventors: Mario Stevenson, Rajnish Kaushik, Xiaonan Zhu
-
Publication number: 20150118250Abstract: The present invention relates to a recombinant avian herpes virus, which comprises at least two recombinant nucleotide sequences, each recombinant nucleotide sequence encoding a distinct antigenic peptide, wherein said at least two recombinant nucleotide sequences are inserted into distinct non-coding region of the viral genome chosen among the region located between UL44 and UL45, the region located between UL45 and UL46, the region located between US10 and SORF3, the region located between SORF3 and US2.Type: ApplicationFiled: March 29, 2013Publication date: April 30, 2015Inventors: Ayumi Fujisawa, Mayumi Kubomura, Sakiko Saeki, Shuji Saito
-
Publication number: 20150110835Abstract: The present invention provides a recombinant turkey herpesvirus modified by the presence of the cDNA encoding the hemagglutinin protein of avian influenza virus under a promoter. A poultry vaccine comprising the recombinant turkey herpesvirus described in the present invention can induce serological responses that may be easily detected by the hemagglutination inhibition assay but not by commercially available diagnostic ELISA kits; thus enabling easy differentiation between vaccination and field infection.Type: ApplicationFiled: November 24, 2014Publication date: April 23, 2015Inventors: Motoyuki ESAKI, Lauren Elizabeth Jensen, Kristi M. Dorsey
-
Patent number: 9011872Abstract: An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. The method generally involves the steps of transfecting recombinant virus containing open reading frame 2 coding sequences into cells contained in growth media, causing the virus to express open reading frame 2, and recovering the expressed protein in the supernate. This recovery should take place beginning approximately 5 days after infection of the cells in order to permit sufficient quantities of recombinant protein to be expressed and secreted from the cell into the growth media. Such methods avoid costly and time-consuming extraction procedures required to separate and recover the recombinant protein from within the cells.Type: GrantFiled: December 27, 2012Date of Patent: April 21, 2015Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Marc Allan Eichmeyer, Gregory Paul Nitzel, Merrill Lynn Schaeffer
-
Patent number: 8999946Abstract: The present invention provides chimeric adenoviral vectors and methods for using the vectors to elicit an immune response to an antigen of interest.Type: GrantFiled: June 25, 2012Date of Patent: April 7, 2015Assignee: Vaxart, Inc.Inventor: Sean N. Tucker
-
Patent number: 8986706Abstract: The present invention encompasses recombinant Newcastle Disease Virus-Herpesvirus vaccines or compositions. The invention encompasses recombinant NDV vectors encoding and expressing herpesvirus pathogen, antigens, proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals against disease.Type: GrantFiled: August 29, 2011Date of Patent: March 24, 2015Assignee: Merial, Inc.Inventors: Michel Bublot, Frederic Reynard, Herve Poulet, Frederic Raymond David
-
Patent number: 8986987Abstract: The present application applies to the field of veterinary vaccines, in particular of vaccines for poultry against avian influenza. The vaccine is based on a recombinant viral vector expressing the haemagglutinin protein of an influenza virus, wherein the vector is herpes virus of turkeys (HVT) and the haemagglutinin gene is driven by a glycoprotein B gene promoter from a mammalian herpesvirus. A vaccine comprising this HVT+HA vector can be used to induce a protective immune response against avian influenza in poultry, and to reduce the spread of AIV. The invention also relates to methods, uses, and vaccines involving the HVT+HA vector.Type: GrantFiled: October 17, 2011Date of Patent: March 24, 2015Assignee: Intervet Inc.Inventors: Paulus Jacobus Antonius Sondermeijer, Iwan Verstegen
-
Patent number: 8980280Abstract: The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions.Type: GrantFiled: February 2, 2012Date of Patent: March 17, 2015Assignees: Merial, Inc., Centre National de la Recherche Scientifique, Institut Gustave Roussy, Universite Paris-SudInventors: Herve Poulet, Thierry Heidmann
-
Publication number: 20150071962Abstract: Novel simian adenovirus 41 and two isolates thereof are described. Various uses of these isolates, including construction of a recombinant vector which comprises simian adenovirus 41 sequences and a heterologous gene under the control of regulatory sequences are provided. A cell line which expresses simian adenovirus 41 gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.Type: ApplicationFiled: August 19, 2014Publication date: March 12, 2015Inventors: Soumitra Roy, James M. Wilson, Luc H. Vandenberghe
-
Publication number: 20150071964Abstract: Methods and compositions are provided herein for non-invasive administration of an adenoviral vector (Ad-vector) vaccine with an adjuvant, such as a TLR3 agonist. These methods provide, for example, an increase in the immune response to the vaccine, an increase in the immunogenicity of the Ad-vector vaccine, an antigen sparing effect and improved safety with an effective protective immune response to the vaccine.Type: ApplicationFiled: September 5, 2014Publication date: March 12, 2015Applicant: VAXIN INC.Inventor: De-Chu Tang
-
Publication number: 20150071965Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.Type: ApplicationFiled: October 27, 2014Publication date: March 12, 2015Inventors: Paul JOHNSON, Robert L. MARTUZA, Samuel D. RABKIN, Tomoki TODO
-
Publication number: 20150071876Abstract: A combined measles-malaria vaccine containing different attenuated recombinant measles-malaria vectors comprising a heterologous nucleic acid encoding several Plasmodium falciparum antigens is described. Preferably, it relates to viral vectors that comprise nucleic acids encoding the circumsporozoite (CS) protein of P. falciparum, the merozoite surface protein 1 (MSP-1) of P. falciparum, and its derivatives (p-42; p-83-30-38) in its glycosylated and secreted forms, and apical membrane antigen1 (AMA1) of P. falciparum, in its anchored or secreted form. The viral vector stems from an attenuated measles virus, based on a strain that is used as a vaccine and is efficient in delivering the gene of interest and that binds to and infects the relevant immune cells efficiently.Type: ApplicationFiled: September 15, 2014Publication date: March 12, 2015Applicant: CADILA HEALTHCARE LIMITEDInventors: Reinhard GLUECK, Agata FAZIO, Viviana GIANINO, Martin A. BILLETER
-
Publication number: 20150071963Abstract: The invention relates to building a chimeric polypeptide used for preventing or treating a Flaviviridae infection. The use of the inventive chimeric polypeptide for producing recombinant viral vectors such as a measles living viral vector is also disclosed.Type: ApplicationFiled: September 4, 2014Publication date: March 12, 2015Inventors: Frederic TANGY, Marianne LUCAS-HOURANI, Erika NAVARRO-SANCHEZ, Marie-Pascale FRENKIEL, Hugues BEDOUELLE, Chantal COMBREDET, Philippe DESPRES
-
Publication number: 20150064214Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.Type: ApplicationFiled: December 4, 2013Publication date: March 5, 2015Applicant: The USA, as represented by the Secretary, Department of Health & Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai